Jonathan B. Singer
Clinical Pharmacogenetics
Novartis Institutes for Biomedical Research
Cambridge
MA 02139
USA
Name/email consistency: high
- UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Singer, J.B., Shou, Y., Giles, F., Kantarjian, H.M., Hsu, Y., Robeva, A.S., Rae, P., Weitzman, A., Meyer, J.M., Dugan, M., Ottmann, O.G. Leukemia (2007)
- Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Singer, J.B., Holdaas, H., Jardine, A.G., Fellstrøm, B., Os, I., Bermann, G., Meyer, J.M. J. Lipid Res. (2007)